Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

André, Fabrice; Ciruelos, Eva; Juric, Dejan; Loibl, Sibylle; Campone, Mario; A. Mayer, Ingrid; Rubovszky, Gábor; Yamashita, Toshinari; Kaufman, Bella; Lu, Yen‐Shen; Inoue, Kenichi; Pápai, Zsuzsanna; Takahashi, Masato; Ghaznawi, Farhat; Mills, David; Kaper, Mathilde; C. Miller, Michelle; Conte, PierFranco; Iwata, Hiroji; S. Rugo, Hope

doi:10.1016/j.annonc.2020.11.011

Public

Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2–negative advanced breast cancer: final overall survival results from SOLAR-1

Published in Annals of Oncology • Nov 24, 2020

Authors:

Fabrice André

Eva Ciruelos

Dejan Juric

Abstract

BACKGROUND: Activation of the phosphatidylinositol-3-kinase (PI3K) pathway via PIK3CA mutations occurs in 28%-46% of hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-) advanced breast cancers (ABCs) and is associated with poor prognosis. The SOLAR-1 trial show...

Subject

Fulvestrant

Medicine

Human Epidermal Growth Factor Receptor 2

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!